evans blue has been researched along with Leukemia L 1210 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bibby, MC; Burger, AM; Duncan, R; Fiebig, HH; Sat-Klopsch, YN; Sausville, EA | 1 |
| Balzarini, J; Broder, S; De Clercq, E; Mitsuya, H | 1 |
2 other study(ies) available for evans blue and Leukemia L 1210
| Article | Year |
|---|---|
Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate.
Topics: Acrylamides; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cathepsin B; Cell Line, Tumor; Coloring Agents; Delayed-Action Preparations; Disease Models, Animal; Doxorubicin; Evans Blue; Humans; Leukemia L1210; Mice; Nanotechnology; Permeability; Polyglutamic Acid; Polymers; Xenograft Model Antitumor Assays | 2013 |
Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus.
Topics: Animals; Aurintricarboxylic Acid; Azo Compounds; Benzhydryl Compounds; Cell Division; Cyclohexanecarboxylic Acids; Cytopathogenic Effect, Viral; Deltaretrovirus; Evans Blue; Injections, Intraperitoneal; Leukemia L1210; Leukemia, Erythroblastic, Acute; Mammary Neoplasms, Experimental; Mice; Suramin; Viral Proteins | 1986 |